Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

NKTR Nektar Therapeutics

1,03

0,00 (0,00%)

Nach Börsenschluss

Zuletzt aktualisiert: 00:01:50

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Nektar Therapeutics Charts.

Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Nektar Therapeutics Charts.

News Nektar Therapeutics

Form 144 - Report of proposed sale of securities
Dienstag 19 November 2024 (3 Stunden vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 19 November 2024 (4 Stunden vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 19 November 2024 (4 Stunden vor) • Edgar (US Regulatory)

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Montag 18 November 2024 (1 Tag vor) • PR Newswire (US)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Donnerstag 14 November 2024 (5 Tage vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (5 Tage vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 8 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Donnerstag 7 November 2024 (2 Wochen vor) • PR Newswire (US)

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Donnerstag 7 November 2024 (2 Wochen vor) • PR Newswire (US)

Nektar Therapeutics to Participate in Upcoming Investor Conferences
Donnerstag 7 November 2024 (2 Wochen vor) • PR Newswire (US)

Form 8-K - Current report
Montag 4 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Weitere Nektar Therapeutics News-Artikel

JP Morgan Chase

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Deutsche Telekom (QX)

Health Care Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen